<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726098</url>
  </required_header>
  <id_info>
    <org_study_id>HIGHLOWDEXA-COVID</org_study_id>
    <secondary_id>2020-005702-25</secondary_id>
    <nct_id>NCT04726098</nct_id>
  </id_info>
  <brief_title>Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19</brief_title>
  <acronym>HIGHLOWDEXA</acronym>
  <official_title>Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manuel Taboada Muñiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      After RECOVERY trial publication, low dose (6 mg dexamethasone for 10 days) was recommended&#xD;
      as the usual care treatment in hospitalized patients with respiratory failure by COVID-19&#xD;
      needing oxygen therapy. RECOVERY trial showed how the use of dexamethasone 6 mg / day for ten&#xD;
      days compared to standard treatment without the use of corticosteroids in hospitalized&#xD;
      patients reduced mortality at 28 days (22.9% with dexamethasone vs 25.7% without&#xD;
      dexamethasone). In the dexamethasone group, the incidence of mortality was lower than&#xD;
      standard treatment in patients with hypoxia and the need for mechanical ventilation (29.3%&#xD;
      with dexamethasone vs 41.4% without dexamethasone), in patients admitted to the hospital ward&#xD;
      with a need for oxygen therapy (23.3% with dexamethasone vs 26.2% without dexamethasone), but&#xD;
      they did not find differences between those admitted patients who did not need oxygen&#xD;
      therapy. There are two other studies (DEXA-COVID-19 and CoDEX) where they observed benefits&#xD;
      of the use of dexamethasone 20 mg / day 5 days, and 10 mg / day 5 days (total 10 days) in&#xD;
      patients admitted for respiratory distress syndrome (ARDS) and COVID-19. At present, it is&#xD;
      unclear what dose of dexamethasone is most beneficial in patients with COVID-19 and&#xD;
      respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The investigators aim to assess the efficacy of high dose of dexamethasone (20 mg&#xD;
      / day 5 days, and 10 mg/day 5 days) versus low dose of dexamethasone (6 mg/day 10 days) in&#xD;
      patients with respiratory failure by COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, open-label trial involving hospitalized adult patients with respiratory failure needing oxygen therapy, caused by COVID-19.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with treatment failure at day 11</measure>
    <time_frame>Day 11 after randomization</time_frame>
    <description>defined as death, need of ICU and extracorporeal membrane oxygenation, need of non-invasive ventilation or nasal high-flow oxygen therapy, or worsening of the condition clinic of the patient during treatment (two of these: need to increase Fraction of inspired oxygen inspired&gt;20%, need for fraction inspired oxygenation&gt;50%, increase in respiratory rate&gt;25, increase in inflammatory markers).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without the need for oxygen support at day 11.</measure>
    <time_frame>Day 11 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-days mortality</measure>
    <time_frame>28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status of patients using the World Health Organization 7-point Ordinal Scale for clinical improvement during 10 days of treatment</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>1:Not hospitalized, 2:Hospitalized and not treatment, 3: Hospitalized with treatment, not requiring supplemental oxygen, 4:Hospitalized requiring supplemental oxygen, 5:Hospitalized, requiring non-invasive ventilation or nasal high-flow oxygen therapy, 6: Hospitalized requiring invasive ventilation or Extracorporeal (ECMO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing Intensive Care Unit admission</measure>
    <time_frame>28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing invasive mechanical ventilation or extracorporeal membrane oxygenation</measure>
    <time_frame>28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing non-invasive ventilation or nasal high-flow oxygen therapy</measure>
    <time_frame>28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications during hospital admission</measure>
    <time_frame>90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>11 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Covid19</condition>
  <condition>Corticosteroids</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 6mg/day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 20mg/day for 5 days + Dexamethasone 10mg/day for 5 days (Total 10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone high dose</intervention_name>
    <description>High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone low dose</intervention_name>
    <description>Low doses: dexamethasone 6 mg/day 10 days.</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Hospitalized COVID-19 patients admitted to the Hospital.&#xD;
&#xD;
          -  Patients requiring supplemental oxygen. Level 4 using the World Health Organization&#xD;
             7-point Ordinal Scale for clinical improvement&#xD;
&#xD;
          -  Patients requiring corticosteroids (dexamethasone) according to Hospital protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or active lactation.&#xD;
&#xD;
          -  Patient is expected to die in the next 48 hours.&#xD;
&#xD;
          -  Known history of dexamethasone allergy or known contraindication to the use of&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Daily use of corticosteroids in the past 15 days.&#xD;
&#xD;
          -  Indication for corticosteroids use for other clinical conditions (e.g. refractory&#xD;
             septic shock).&#xD;
&#xD;
          -  Consent refusal for participating in the trial.&#xD;
&#xD;
          -  Different level of 4 in Level 4 using the World Health Organization 7-point Ordinal&#xD;
             Scale for clinical improvement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Taboada Muñiz, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinical Hospital of Santiago de Compostela</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Taboada Muñiz, Ph.D.</last_name>
    <phone>+34678195618</phone>
    <email>manutabo@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Teresa Cabaleiro Ocampo</last_name>
    <phone>+34 981 951 628</phone>
    <phone_ext>251628</phone_ext>
    <email>ma.teresa.cabaleiro.ocampo@sergas.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Hospital of Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15866</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Taboada Muñiz, Ph.D.</last_name>
      <phone>+34678195618</phone>
      <email>manutabo@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>María Teresa Cabaleiro Ocampo</last_name>
      <phone>+34 981 951 628</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Manuel Taboada Muñiz</investigator_full_name>
    <investigator_title>Associate Proffesor</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

